Association Between Prehospital Tranexamic Acid Administration and Outcomes of Severe Traumatic Brain Injury
Authors: Sebastiaan M. Bossers, Stephan A. Loer, Frank W. Bloemers, Dennis Den Hartog, Esther M. M. Van Lieshout, Nico Hoogerwerf, Joukje van der Naalt, Anthony R. Absalom, Saskia M. Peerdeman, Lothar A. Schwarte, Christa Boer, Patrick Schober, Anne de Boer, Johannes C. Goslings, Sven H. van Helden, Danique Hesselink, Gijs van Aken, Albertus Beishuizen, Rolf E. Egberink, Nancy ter Bogt, Mariska A.C. de Jongh, Koen Lansink, Gerwin Roks, Pieter Joosse, Kees J. Ponsen, Lukas L. van Spengler, Stasja Aspers, Annelies Toor, Robert J. Houmes, Jan van Ditshuizen, Tea van Voorden, Michael J.R. Edwards, Bert Dercksen, Rob Spanjersberg, Lieneke F. Venema, Ellen Weelink, Inge H.F. Reininga, Gerard Innemee, Matthijs de Visser, Marcel A. de Leeuw
Journal: JAMA Neurology (2020)

The development and expansion of intracranial hematoma are associated with adverse outcomes. Use of tranexamic acid might limit intracranial hematoma formation, but its association with outcomes of severe traumatic brain injury (TBI) is unclear.To assess whether prehospital administration of tranexamic acid is associated with mortality and functional outcomes in a group of patients with severe TBI.This multicenter cohort study is an analysis of prospectively collected observational data from the Brain Injury: Prehospital Registry of Outcome, Treatments and Epidemiology of Cerebral Trauma (BRAIN-PROTECT) study in the Netherlands. Patients treated for suspected severe TBI by the Dutch Helicopter Emergency Medical Services between February 2012 and December 2017 were included. Patients were followed up for 1 year after inclusion. Data were analyzed from January 10, 2020, to September 10, 2020.Administration of tranexamic acid during prehospital treatment.The primary outcome was 30-day mortality. Secondary outcomes included mortality at 1 year, functional neurological recovery at discharge (measured by Glasgow Outcome Scale), and length of hospital stay. Data were also collected on demographic factors, preinjury medical condition, injury characteristics, operational characteristics, and prehospital vital parameters.A total of 1827 patients were analyzed, of whom 1283 (70%) were male individuals and the median (interquartile range) age was 45 (23-65) years. In the unadjusted analysis, higher 30-day mortality was observed in patients who received prehospital tranexamic acid (odds ratio [OR], 1.34; 95% CI, 1.16-1.55; P < .001), compared with patients who did not receive prehospital tranexamic acid. After adjustment for confounders, no association between prehospital administration of tranexamic acid and mortality was found across the entire cohort of patients. However, a substantial increase in the odds of 30-day mortality persisted in patients with severe isolated TBI who received prehospital tranexamic acid (OR, 4.49; 95% CI, 1.57-12.87; P = .005) and after multiple imputations (OR, 2.05; 95% CI, 1.22-3.45; P = .007).This study found that prehospital tranexamic acid administration was associated with increased mortality in patients with isolated severe TBI, suggesting the judicious use of the drug when no evidence for extracranial hemorrhage is present.